Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy
COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal vaccination with Ad26.COV2.S COVID-19 vaccine and monitored serum and breast milk antibody levels in mothers and infants until 6 months post-...
Uloženo v:
| Vydáno v: | Human vaccines & immunotherapeutics Ročník 21; číslo 1; s. 2538340 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Taylor & Francis
01.12.2025
Taylor & Francis Group |
| Témata: | |
| ISSN: | 2164-5515, 2164-554X, 2164-554X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal vaccination with Ad26.COV2.S COVID-19 vaccine and monitored serum and breast milk antibody levels in mothers and infants until 6 months post-delivery. This open-label Phase 2 study enrolled previously COVID-19 vaccinated or COVID-19-vaccine-naive healthy pregnant women in trimester two or three (NCT04765384). All women received a single dose of Ad26.COV2.S. Mothers and infants were followed-up for safety until 1-year post-partum and for immunogenicity, including antibodies in breast milk, until 6 months post-partum. Recruitment was stopped at 51 participants due to rapidity of roll-out of COVID-19 vaccines recommended during pregnancy. Ad26.COV2.S was well-tolerated regardless of previous COVID-19 vaccination history. All pregnancies resulted in a live infant, four were preterm. One serious adverse event of placental insufficiency Day-36 post-vaccination was considered vaccine-related by the investigator. One infant died due to complications associated with an unrelated ventricular septal defect. Ad26.COV2.S induced robust immune responses in women with different COVID-19 vaccination histories. Spike-binding antibody (SAbs) and virus neutralizing antibody (NAbs) titers at delivery tended to be higher in mothers vaccinated during trimester three. Maternal serum and cord blood were strongly correlated. 100% of infants had detectable SAbs at aged 6 months, and 70.6% had detectable NAbs, including 68.2% born to initially vaccine-naïve mothers. Maternal vaccination with an adenovirus-vector vaccine was well-tolerated and immunogenic in mothers and infants. These data could support the adoption of heterologous booster regimens during pregnancy and future adenovirus-vector vaccine development. |
|---|---|
| AbstractList | COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal vaccination with Ad26.COV2.S COVID-19 vaccine and monitored serum and breast milk antibody levels in mothers and infants until 6 months post-delivery. This open-label Phase 2 study enrolled previously COVID-19 vaccinated or COVID-19-vaccine-naive healthy pregnant women in trimester two or three (NCT04765384). All women received a single dose of Ad26.COV2.S. Mothers and infants were followed-up for safety until 1-year post-partum and for immunogenicity, including antibodies in breast milk, until 6 months post-partum. Recruitment was stopped at 51 participants due to rapidity of roll-out of COVID-19 vaccines recommended during pregnancy. Ad26.COV2.S was well-tolerated regardless of previous COVID-19 vaccination history. All pregnancies resulted in a live infant, four were preterm. One serious adverse event of placental insufficiency Day-36 post-vaccination was considered vaccine-related by the investigator. One infant died due to complications associated with an unrelated ventricular septal defect. Ad26.COV2.S induced robust immune responses in women with different COVID-19 vaccination histories. Spike-binding antibody (SAbs) and virus neutralizing antibody (NAbs) titers at delivery tended to be higher in mothers vaccinated during trimester three. Maternal serum and cord blood were strongly correlated. 100% of infants had detectable SAbs at aged 6 months, and 70.6% had detectable NAbs, including 68.2% born to initially vaccine-naïve mothers. Maternal vaccination with an adenovirus-vector vaccine was well-tolerated and immunogenic in mothers and infants. These data could support the adoption of heterologous booster regimens during pregnancy and future adenovirus-vector vaccine development. COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal vaccination with Ad26.COV2.S COVID-19 vaccine and monitored serum and breast milk antibody levels in mothers and infants until 6 months post-delivery. This open-label Phase 2 study enrolled previously COVID-19 vaccinated or COVID-19-vaccine-naive healthy pregnant women in trimester two or three (NCT04765384). All women received a single dose of Ad26.COV2.S. Mothers and infants were followed-up for safety until 1-year post-partum and for immunogenicity, including antibodies in breast milk, until 6 months post-partum. Recruitment was stopped at 51 participants due to rapidity of roll-out of COVID-19 vaccines recommended during pregnancy. Ad26.COV2.S was well-tolerated regardless of previous COVID-19 vaccination history. All pregnancies resulted in a live infant, four were preterm. One serious adverse event of placental insufficiency Day-36 post-vaccination was considered vaccine-related by the investigator. One infant died due to complications associated with an unrelated ventricular septal defect. Ad26.COV2.S induced robust immune responses in women with different COVID-19 vaccination histories. Spike-binding antibody (SAbs) and virus neutralizing antibody (NAbs) titers at delivery tended to be higher in mothers vaccinated during trimester three. Maternal serum and cord blood were strongly correlated. 100% of infants had detectable SAbs at aged 6 months, and 70.6% had detectable NAbs, including 68.2% born to initially vaccine-naïve mothers. Maternal vaccination with an adenovirus-vector vaccine was well-tolerated and immunogenic in mothers and infants. These data could support the adoption of heterologous booster regimens during pregnancy and future adenovirus-vector vaccine development.COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal vaccination with Ad26.COV2.S COVID-19 vaccine and monitored serum and breast milk antibody levels in mothers and infants until 6 months post-delivery. This open-label Phase 2 study enrolled previously COVID-19 vaccinated or COVID-19-vaccine-naive healthy pregnant women in trimester two or three (NCT04765384). All women received a single dose of Ad26.COV2.S. Mothers and infants were followed-up for safety until 1-year post-partum and for immunogenicity, including antibodies in breast milk, until 6 months post-partum. Recruitment was stopped at 51 participants due to rapidity of roll-out of COVID-19 vaccines recommended during pregnancy. Ad26.COV2.S was well-tolerated regardless of previous COVID-19 vaccination history. All pregnancies resulted in a live infant, four were preterm. One serious adverse event of placental insufficiency Day-36 post-vaccination was considered vaccine-related by the investigator. One infant died due to complications associated with an unrelated ventricular septal defect. Ad26.COV2.S induced robust immune responses in women with different COVID-19 vaccination histories. Spike-binding antibody (SAbs) and virus neutralizing antibody (NAbs) titers at delivery tended to be higher in mothers vaccinated during trimester three. Maternal serum and cord blood were strongly correlated. 100% of infants had detectable SAbs at aged 6 months, and 70.6% had detectable NAbs, including 68.2% born to initially vaccine-naïve mothers. Maternal vaccination with an adenovirus-vector vaccine was well-tolerated and immunogenic in mothers and infants. These data could support the adoption of heterologous booster regimens during pregnancy and future adenovirus-vector vaccine development. |
| Author | Lowson, David Struyf, Frank Rezelj, Veronica V. Maximos, Bassem Le Gars, Mathieu Robinson, Cynthia Aguilar, Gloria de Groot, Anne Marit Bet, Nicole Tapia-Calle, Gabriela Baron, Benoit van Paassen, Vitalija Ruiz-Guiñazú, Javier |
| Author_xml | – sequence: 1 givenname: Gloria surname: Aguilar fullname: Aguilar, Gloria – sequence: 2 givenname: Gabriela surname: Tapia-Calle fullname: Tapia-Calle, Gabriela – sequence: 3 givenname: Cynthia surname: Robinson fullname: Robinson, Cynthia – sequence: 4 givenname: Benoit surname: Baron fullname: Baron, Benoit – sequence: 5 givenname: David surname: Lowson fullname: Lowson, David – sequence: 6 givenname: Bassem surname: Maximos fullname: Maximos, Bassem – sequence: 7 givenname: Veronica V. surname: Rezelj fullname: Rezelj, Veronica V. – sequence: 8 givenname: Anne Marit surname: de Groot fullname: de Groot, Anne Marit – sequence: 9 givenname: Nicole surname: Bet fullname: Bet, Nicole – sequence: 10 givenname: Vitalija surname: van Paassen fullname: van Paassen, Vitalija – sequence: 11 givenname: Mathieu surname: Le Gars fullname: Le Gars, Mathieu – sequence: 12 givenname: Frank surname: Struyf fullname: Struyf, Frank – sequence: 13 givenname: Javier surname: Ruiz-Guiñazú fullname: Ruiz-Guiñazú, Javier |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40808283$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkk1vEzEQhleoiJbSnwDykQNb_LnrnBAKX5Eq9UCFuFne8WziKmsH2xuUv8EvZtOkgfpgj8aPnjnM-7I6CzFgVb1m9JpRTd9z1kilmLrmlE-XElpI-qy62PdrpeTPs1PN1Hl1lfM9nU5LuWyaF9W5nCSaa3FR_flueyy7d8QPwxjiEoMHX3bEBkc2CZfBBtiROBaIA2biAxliWWHKD4QPvQ1lqvuCiWwtgA-2-BjIb19WE0KswxC3Po253iKUmMj89sfiU81mRxyJG5MPy3_TXlXPe7vOeHV8L6u7L5_v5t_qm9uvi_nHmxqEZqXmgC21AqADBVI557DhlkmnnOWag5TYKCdor8F1VFDouW5F14LutW5BXFaLg9ZFe282yQ827Uy03jw0Yloam4qHNZoZd0oIrRrJO2lb6JA5B7OezgS0vMHJ9eHg2ozdgA4wlGTXT6RPf4JfmWXcGsaFUk3bTIa3R0OKv0bMxQw-A67XNmAcsxFczCTlQtAJffP_sNOUx6VOgDoAkGLOCfsTwqjZ58c85sfs82OO-RF_Ac0su1E |
| Cites_doi | 10.2185/jrm.2022-025 10.3390/ijms242316591 10.15585/mmwr.mm7239a3 10.1056/NEJMoa2034201 10.1055/a-2090-5402 10.7759/cureus.59500 10.1016/j.vaccine.2020.09.018 10.1001/jamanetworkopen.2023.42475 10.1002/bit.28553 10.3390/vaccines12080825 10.3389/fimmu.2020.607333 10.1159/000501906 10.1016/j.cmi.2021.10.003 10.1038/s41541-023-00698-8 10.15585/mmwr.mm7107e3 10.1001/jama.2022.1206 10.7759/cureus.54306 10.1016/j.vaccine.2023.03.038 10.1093/cid/ciac080 10.1038/s41467-022-31169-8 10.1186/s12884-021-03772-y 10.1038/s41541-020-00243-x 10.1016/j.siny.2023.101433 |
| ContentType | Journal Article |
| Copyright | 2025 Johnson & Johnson. Published with license by Taylor & Francis Group, LLC. 2025 Johnson & Johnson |
| Copyright_xml | – notice: 2025 Johnson & Johnson. Published with license by Taylor & Francis Group, LLC. 2025 Johnson & Johnson |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1080/21645515.2025.2538340 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | G. AGUILAR ET AL |
| EISSN | 2164-554X |
| ExternalDocumentID | oai_doaj_org_article_92d53385642b4a7cbe1ddc9f093c726e PMC12355676 40808283 10_1080_21645515_2025_2538340 |
| Genre | Clinical Trial, Phase II Journal Article |
| GroupedDBID | --- 00X 0YH 30N 4.4 53G AALUX AAYXX ABEIZ ABUPF ACGFS ADBBV ADCVX AECIN AENEX AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS AQTUD ARJSQ BABNJ BAWUL BLEHA BOHLJ CCCUG CITATION EBS EMOBN GROUPED_DOAJ H13 KYCEM LJTGL M4Z O9- RPM SV3 TDBHL TFL TFW TTHFI 0VX CGR CUY CVF DGEBU DIK ECM EIF EJD HYE IPNFZ NPM OVD RIG TEORI 7X8 5PM |
| ID | FETCH-LOGICAL-c381t-2ce70a3ccbc5c45ddde62a14d5da282c44e65d30f8cdb030cf2873b7c8f887c3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001550228500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2164-5515 2164-554X |
| IngestDate | Fri Oct 03 12:43:50 EDT 2025 Tue Nov 04 02:04:48 EST 2025 Fri Sep 05 15:10:20 EDT 2025 Thu Sep 11 02:53:25 EDT 2025 Sat Nov 29 07:36:52 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 passive antibody transfer SARS-CoV-2 vaccine pregnancy Adenovirus vectors neonates |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c381t-2ce70a3ccbc5c45ddde62a14d5da282c44e65d30f8cdb030cf2873b7c8f887c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: GSK, Avenue Fleming 20, 1300 Wavre, Belgium. Present address: AstraZeneca, Barcelona, Spain. |
| OpenAccessLink | https://doaj.org/article/92d53385642b4a7cbe1ddc9f093c726e |
| PMID | 40808283 |
| PQID | 3239402330 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_92d53385642b4a7cbe1ddc9f093c726e pubmedcentral_primary_oai_pubmedcentral_nih_gov_12355676 proquest_miscellaneous_3239402330 pubmed_primary_40808283 crossref_primary_10_1080_21645515_2025_2538340 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Dec |
| PublicationDateYYYYMMDD | 2025-12-01 |
| PublicationDate_xml | – month: 12 year: 2025 text: 2025-Dec |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Human vaccines & immunotherapeutics |
| PublicationTitleAlternate | Hum Vaccin Immunother |
| PublicationYear | 2025 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | e_1_3_5_27_1 e_1_3_5_26_1 e_1_3_5_25_1 e_1_3_5_24_1 e_1_3_5_23_1 e_1_3_5_22_1 e_1_3_5_3_1 e_1_3_5_2_1 e_1_3_5_9_1 e_1_3_5_21_1 e_1_3_5_8_1 e_1_3_5_20_1 e_1_3_5_5_1 e_1_3_5_4_1 e_1_3_5_7_1 e_1_3_5_6_1 e_1_3_5_18_1 e_1_3_5_17_1 e_1_3_5_16_1 e_1_3_5_13_1 e_1_3_5_14_1 Romero Otalvaro AM (e_1_3_5_15_1) 2018; 116 e_1_3_5_11_1 e_1_3_5_12_1 e_1_3_5_19_1 e_1_3_5_10_1 |
| References_xml | – ident: e_1_3_5_20_1 doi: 10.2185/jrm.2022-025 – ident: e_1_3_5_13_1 doi: 10.3390/ijms242316591 – ident: e_1_3_5_7_1 doi: 10.15585/mmwr.mm7239a3 – ident: e_1_3_5_16_1 – ident: e_1_3_5_14_1 doi: 10.1056/NEJMoa2034201 – ident: e_1_3_5_24_1 doi: 10.1055/a-2090-5402 – ident: e_1_3_5_27_1 doi: 10.7759/cureus.59500 – ident: e_1_3_5_11_1 doi: 10.1016/j.vaccine.2020.09.018 – ident: e_1_3_5_2_1 – ident: e_1_3_5_6_1 doi: 10.1001/jamanetworkopen.2023.42475 – ident: e_1_3_5_10_1 doi: 10.1002/bit.28553 – ident: e_1_3_5_19_1 doi: 10.3390/vaccines12080825 – ident: e_1_3_5_12_1 doi: 10.3389/fimmu.2020.607333 – ident: e_1_3_5_17_1 doi: 10.1159/000501906 – volume: 116 start-page: 7 issue: 1 year: 2018 ident: e_1_3_5_15_1 article-title: ASQ-3: validation of the ages and stages questionnaire for the detection of neurodevelopmental disorders in Argentine children publication-title: Arch Argent Pediatr – ident: e_1_3_5_25_1 doi: 10.1016/j.cmi.2021.10.003 – ident: e_1_3_5_23_1 doi: 10.1038/s41541-023-00698-8 – ident: e_1_3_5_8_1 doi: 10.15585/mmwr.mm7107e3 – ident: e_1_3_5_26_1 doi: 10.1001/jama.2022.1206 – ident: e_1_3_5_4_1 doi: 10.7759/cureus.54306 – ident: e_1_3_5_18_1 doi: 10.1016/j.vaccine.2023.03.038 – ident: e_1_3_5_21_1 doi: 10.1093/cid/ciac080 – ident: e_1_3_5_22_1 doi: 10.1038/s41467-022-31169-8 – ident: e_1_3_5_3_1 doi: 10.1186/s12884-021-03772-y – ident: e_1_3_5_9_1 doi: 10.1038/s41541-020-00243-x – ident: e_1_3_5_5_1 doi: 10.1016/j.siny.2023.101433 |
| SSID | ssj0000702466 |
| Score | 2.3747056 |
| Snippet | COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 2538340 |
| SubjectTerms | Adenoviridae - genetics Adenovirus vectors Adult Antibodies, Neutralizing - blood Antibodies, Viral - analysis Antibodies, Viral - blood Coronavirus COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Female Humans Immunogenicity, Vaccine Infant Infant, Newborn Milk, Human - immunology neonates passive antibody transfer Pregnancy Pregnancy Complications, Infectious - immunology Pregnancy Complications, Infectious - prevention & control Pregnancy Outcome SARS-CoV-2 SARS-CoV-2 - immunology Vaccination Young Adult |
| Title | Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40808283 https://www.proquest.com/docview/3239402330 https://pubmed.ncbi.nlm.nih.gov/PMC12355676 https://doaj.org/article/92d53385642b4a7cbe1ddc9f093c726e |
| Volume | 21 |
| WOSCitedRecordID | wos001550228500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: DOA dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: TFW dateStart: 20180102 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: 0YH dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LbtQw0IIKJC6Id5dHZSSOmCZ-xM4RSqsioYJEVS2nyBnbkEOTapNdaX-DL2bsZMsuqsSFSw7OSB55xvPyPAh5oxTPbBEsc0IZJoU0zDquWMhBZ7L2ElLK_8VnfXZm5vPy69aor5gTNrYHHg_usOQOLRKj0E6updVQ-9w5KAN64qB54aP0zXS55UwlGaxR96SHSo7-AEOzQG3Kd0x2GNfiErqHHD9450UMfmwpptS__yaj8-_cyS1ldPKA3J-sSPp-xP4hueXbR-TuOFdy_Zj8-maDH9ZvaROrPzrkkQbQ2qa2dfRq4X_EJhtr2i0HZDff06all6kQq08QyHMxOYam8eF0ZQGaMWRIY9AWQahFYdWtmsWyZ6sU9adHXy4-fWR5OYF7OpY__tntCTk_OT4_OmXT8AUGqMQHxsHrzAqAGhRI5VAMFtzm0iln0U0DKX2hnMiCAVejpICAvpeoNZiAcgvEU7LXdq3fJ9QX1mS1zOoQchlAWqudz4PIHaCw0GpG3m0OvroaW2xU-dS5dEOpKlKqmig1Ix8iea6BY4fstIB8U018U_2Lb2bk9Ya4Fd6o-ExiW98t-0qkafFcCNzo2Ujs660kIoU-qpgRs8MGO7js_mmbn6lrdyxKVoUunv8P7F-Qe_FExryal2RvWCz9K3IHVkPTLw7I7ez7KX713Byke_EbvVMQVA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+immunogenicity+and+pregnancy+outcomes+in+mothers+and+infants+after+vaccination+with+an+adenovirus-vector+COVID-19+vaccine+during+pregnancy&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Aguilar%2C+Gloria&rft.au=Tapia-Calle%2C+Gabriela&rft.au=Robinson%2C+Cynthia&rft.au=Baron%2C+Benoit&rft.date=2025-12-01&rft.pub=Taylor+%26+Francis&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1080%2F21645515.2025.2538340&rft_id=info%3Apmid%2F40808283&rft.externalDocID=PMC12355676 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon |